Abstract
Objective To investigate the clinical effect of levosimendan in perioperative aortic and/or mitral valve replacement. Methods Patients undergoing open heart aortic and/or mitral valve replacement in our hospital from January 2018 to December 2019 were enrolled. 45 patients in the control group received routine perioperative treatment based on dopamine, while 45 patients in the research group received continuous perioperative administration of levosimendan injection for 24h on the basis of routine treatment. The left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDd) and left ventricular end-systolic diameter (LVDs) were evaluated by color doppler echocardiography before and one week after surgery. Postoperative mechanical ventilation weaning time, length of ICU stays, number of vasoactive drugs used and withdrawal time; indexes of liver and kidney function before and on the day after surgery to 10 days after surgery; use of in vitro support techniques such as aortic balloon pulsation (IABP), continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) within 5 days of perioperative period. Results The improvement of LVDs and LVEF in the study group using levosimendan one week after the operation was significantly better than that in the control group (P value was 0.013 and 0.001, respectively), and fewer kinds of vasoactive drugs were needed (P<0.001), and the risk of postoperative AKI in the study group was significantly lower than that in the control group (P=0.047). Conclusion The perioperative use of levosimendan can effectively promote the recovery of cardiac systolic function and reduce the risk of postoperative AKI.
Keywords
Full Text:
References
Ahmed I, House CM, Nelson WB. Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB). J Cardiothorac Surg. 2009; 4: 24.
Follath F, Cleland JG, Just H, Papp JGY, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328):196-202.
Nieminen MS. Levosimendan compared with dobutamine in low output patients. Minerva Anestesiol. 2003; 69(4): 258-263.
Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail. 2003; 5(1): 101-108.
Duan L, Hu G, Jiang M, Zhang C. Postoperative abnormal liver function in children with heart surgery. J Cent South Univ (Med Sci). 2018; 43(9): 1007-1013.
Rudiger A, Businger F, Streit M, Schmid ER, Maggiorini M, Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Med Wkly. 2009; 139: 110–116.
Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996; 112: 38–51.
Açil T, Türköz R, Açil M, Sezgin AT, Baltali M, Gülcan O, Ozin B, Müderriso?lu H. Value of prolonged QRS duration as a predictor of low cardiac output syndrome in patients with impaired left ventricular systolic function who undergo isolated coronary artery bypass grafting. Am J Cardiol. 2006; 98: 1357–1362.
Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009; 119: 2444–2453.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52:1 527–1539.
Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score matched analysis. Anesthesiology. 2014; 120: 1098–1108.
Toller W, Heringlake M, Guarracino F, Algotsson L, Alvarez J, Argyriadou H, Ben-Gal T, ?erný V, Cholley B, Eremenko A, Guerrero-Orriach JL, Järvelä K, Karanovic N, Kivikko M, Lahtinen P, Lomivorotov V, Mehta RH, Muši? S, Pollesello P, Rex SR, Riha H, Rudiger A, Salmenperä M, Szudi L, Tritapepe L, Wyncoll D, Öwall A. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015; 184: 323–336.
Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabrò MG, Grigoryev EV, Likhvantsev VV, Salgado-Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A, Cheetah Study Group. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017; 376(21): 2021-2031.
Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, Soltesz EG, Luber J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, Alexander JH, LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017; 376(21): 2032-2042.
Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, Miguet B, Guinet P, Lévy F, Squara P, Hamou NA, Carillion A, Boyer J, Boughenou MF, Rosier S, Robin E, Radutoiu M, Durand M, Guidon C, Desebbe O, Charles-Nelson A, Menasché P, Rozec B, Girard C, Fellahi JL, Pirracchio R, Chatellier G. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass. JAMA. 2017; 318(6): 548-556.
Harrison RW, Hasselblad V, Mehta RH, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013; 27: 1224–1232.
Putzu A, Clivio S, Belletti, A, Cassina T. Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. Int J Cardiol. 2018; 251: 22-31.
Qiang H, Luo X, Huo JH, Wang ZQ. Perioperative Use of Levosimendan Improves Clinical Outcomes in Patients After Cardiac Surgery: A Systematic review and meta-analysis. J Cardiovasc Pharmacol. 2018; 72(1): 11-18.
He H, Liu W, Ju M, Liu Y, Gu W, Luo Z. Analysis of factors related to weaning failure of prolonged mechanical ventilation after cardiac surgery. Chin J Clin Med. 2019; 26(5): 727-731.
Chen M. Risk factors for nosocomial infections after cardiac surgery. Chin J Nos. 2013,3: 547-548, 567.
Kandasamy A, Simon HA, Murthy P, Annadurai M, Ali MM, Ramanathan G. Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Ann Card Anaesth. 2017; 20(2): 200-206.
Anastasiadis K, Antonitsis P, Vranis K, Kleontas A, Asteriou C, Grosomanidis V, Tossios P, Argiriadou H. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interact Cardiovasc Thorac Surg. 2016; 23(5):740-747.
Huang Y, Li Y, Wei Y, Liu B, Xu W. Effectiveness of levosimendan versus dobutamine for the patients with severe valvular disease in perioperative period: a randomized controlled trial. Chin J Clin Thorac Cardiovasc Surg. 2015; 22(5): 423-7.
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.